Dr. Meghan Berkenstock is a uveitis subspecialty trained ophthalmologist and an Associate Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins School of Medicine. Her research focuses on identifying ocular adverse events (IRAE) associated with use of immunotherapy agents in the treatment of systemic malignancies. She is a member of the National Comprehensive Cancer Network Panel on developing guidelines to treat IRAEs. She also has served as a panelist on the FDA Oncology Center of Excellence and CDER Office of Oncologic Drugs, Ocular Toxicity Mini Symposium.